SCHEMBL3696376

SCHEMBL3696376

COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(C(=O)/C=C/CN(C)C)CC1

nearest known ligand 0.84

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.84
ERBB2 P04626 4/20 0.80
KCNH2 Q12809 2/20 0.80
RIPK2 O43353 1/20 0.80
RET P07949 1/20 0.80
MET P08581 1/20 0.80
EPHB2 P29323 1/20 0.80
TEC P42680 1/20 0.80
EPHB4 P54760 1/20 0.80
EPHA4 P54764 1/20 0.80
BTK Q06187 1/20 0.80
TNK1 Q13470 1/20 0.80
RIPK3 Q9Y572 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3696381 1.00 EGFR (0.84) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3695012 0.94 EGFR (0.80) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3693232 0.94 EGFR (0.80) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3693237 0.94 EGFR (0.80) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3395848 0.92 EGFR (0.80) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3395846 0.92 EGFR (0.80) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3393406 0.91 EGFR (0.86) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3390747 0.91 EGFR (0.86) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3695363 0.91 EGFR (0.86) EGFRERBB2KCNH2RIPK2RET
SCHEMBL3694745 0.90 EGFR (0.81) EGFRERBB2KCNH2RIPK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3733663-B1 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER CHENGDU JINRUI FOUND BIOTECH CO LTD (CN) 2023-05-17 EP disclosed
EP-3733663-A1 QUINAZOLINE DERIVATIVE AND USE THEREOF Medshine Discovery Inc. (CN) 2020-11-04 EP disclosed
EP-2167492-B1 NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS HANMI SCIENCE CO LTD (KR) 2015-10-14 EP disclosed
US-8188102-B2 Amide derivative for inhibiting the growth of cancer cells HANMI HOLDINGS CO., LTD. (KR) 2012-05-29 US disclosed
US-8188102-B2 Amide derivative for inhibiting the growth of cancer cells HANMI HOLDINGS CO., LTD. (KR) 2012-05-29 US disclosed
US-8188102-B2 Amide derivative for inhibiting the growth of cancer cells HANMI HOLDINGS CO., LTD. (KR) 2012-05-29 US disclosed
US-20100179120-A1 NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS HANMI PHARM. CO., LTD. (KR) 2010-07-15 US disclosed
US-20100179120-A1 NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS HANMI PHARM. CO., LTD. (KR) 2010-07-15 US disclosed
US-20100179120-A1 NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS HANMI PHARM. CO., LTD. (KR) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179120-A1 NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS EGFR, ERBB2, ERBB3 EGFR 1/4885ERBB2 2/4885KCNH2 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.